Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
暂无分享,去创建一个
J. Isola | R. Butzow | A. Leminen | H. Lassus | S. Staff
[1] Luis Serrano,et al. Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.
[2] E. Espinosa,et al. Aurora kinases as prognostic biomarkers in ovarian carcinoma. , 2009, Human pathology.
[3] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[4] Liz Y. Han,et al. Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth , 2008, Clinical Cancer Research.
[5] H. Saya,et al. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice , 2008, Oncogene.
[6] Oliver Gautschi,et al. Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.
[7] Wenlin Huang,et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. , 2007, Cancer research.
[8] J. Ledermann,et al. DNA Replication Licensing Factors and Aurora Kinases are Linked to Aneuploidy and Clinical Outcome in Epithelial Ovarian Carcinoma , 2007, Clinical Cancer Research.
[9] A. Sood,et al. Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients , 2007, Clinical Cancer Research.
[10] A. Walch,et al. Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy , 2007, Clinical Cancer Research.
[11] Qing Jiang,et al. Roles of Aurora Kinases in Mitosis and Tumorigenesis , 2007, Molecular Cancer Research.
[12] Huan Yang,et al. Aurora‐A induces cell survival and chemoresistance by activation of Akt through a p53‐dependent manner in ovarian cancer cells , 2006, International journal of cancer.
[13] Gordon B Mills,et al. Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon , 2005, Clinical Cancer Research.
[14] H. Joensuu,et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma , 2004, British Journal of Cancer.
[15] H. Saya,et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models , 2004, Oncogene.
[16] J. Isola,et al. Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.
[17] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[18] J. Gustafsson,et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. , 2004, Gynecologic oncology.
[19] J. Lundin,et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. , 2003, Gynecologic oncology.
[20] I Vergote,et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] A. Venkitaraman,et al. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.
[22] L. Amundadottir,et al. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[23] Young-Sun Lin,et al. Suppression of the STK15 oncogenic activity requires a transactivation‐independent p53 function , 2002, The EMBO journal.
[24] P. Meraldi,et al. Aurora‐A overexpression reveals tetraploidization as a major route to centrosome amplification in p53−/− cells , 2002, The EMBO journal.
[25] T. Seidal,et al. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. , 2001, International journal of oncology.
[26] H. Nevanlinna,et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. , 1998, British Journal of Cancer.
[27] Jian Kuang,et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.
[28] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[29] Brian Schryver,et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.
[30] S. Sen,et al. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.
[31] H. Risch,et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. , 1996, American journal of epidemiology.
[32] C. Tropé,et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. , 1995, Gynecologic oncology.
[33] W. Sauerbrei,et al. Cellular DNA content and survival in advanced ovarian carcinoma , 1994, Cancer.
[34] E. Pettersen,et al. Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: A prospective study , 1994 .
[35] V. Abeler,et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. , 1993, American journal of obstetrics and gynecology.